RotaTeq®

BIOLOGICAL4 trials

Sponsors

Merck Sharp & Dohme LLC, National Institute of Allergy and Infectious Diseases (NIAID), MCM Vaccines B.V., MSD Wellcome Trust Hilleman Laboratories Pvt. Ltd.

Conditions

Bacterial InfectionsMeningitis, MeningococcalNeisseria MeningitidisRotavirus GastroenteritisRotavirus InfectionRotavirus InfectionsVirus Diseases

Phase 1

Safety, Reactogenicity and Immunogenicity of Heat-stable Rotavirus Vaccine (HSRV) in Adults and Infants

CompletedNCT02728869

MSD Wellcome Trust Hilleman Laboratories Pvt. Ltd.Rotavirus Gastroenteritis

Start: 2016-06-30End: 2017-04-30Updated: 2017-08-21

Phase 3

RotaTeq® and Meningococcus C Vaccine in Healthy Infants (V260-016)

CompletedNCT00443846

Merck Sharp & Dohme LLCMeningitis, Meningococcal, Rotavirus Infections

Start: 2007-02-13End: 2007-10-23Updated: 2018-06-20

Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010)

CompletedNCT01839188

MCM Vaccines B.V.Bacterial Infections, Neisseria Meningitidis, Virus Diseases

Start: 2013-05-01End: 2014-03-19Updated: 2019-02-25

Phase 4

Safety and Immunogenicity of Sequential Rotavirus Vaccine Schedules

CompletedNCT01266850

National Institute of Allergy and Infectious Diseases (NIAID)Rotavirus Infection

Start: 2011-03-31End: 2014-03-31Updated: 2014-10-28

Related Papers

2280. Antibiotic Exposure Does Not Impact Serological Responses to Rotavirus Vaccination

Open Forum Infectious Diseases2018-11-01

Immunogenicity and safety of a new hexavalent vaccine (DTaP5-IPV-HB-Hib) administered in a mixed primary series schedule with a pentavalent vaccine (DTaP5-IPV-Hib).

2017-06-0213 citations